Lois Almadrones

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi request reprint Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study
    Lois Almadrones
    Sloan Kettering Cancer Center, New York, NY, USA
    Oncol Nurs Forum 31:615-23. 2004
  2. ncbi request reprint Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer
    Lois Almadrones
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin J Oncol Nurs 11:211-6. 2007
  3. ncbi request reprint Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group
    David H Moore
    Department of Obstetrics Gynecology, Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 21:4207-13. 2003
  4. ncbi request reprint Chemotherapy-induced peripheral neuropathy
    Terri Armstrong
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Oncol Nurs Forum 32:305-11. 2005

Detail Information

Publications4

  1. ncbi request reprint Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study
    Lois Almadrones
    Sloan Kettering Cancer Center, New York, NY, USA
    Oncol Nurs Forum 31:615-23. 2004
    ..To evaluate the psychometric properties of two adapted scales, one for functional status and one for peripheral neuropathy secondary to neurotoxic chemotherapy...
  2. ncbi request reprint Evidence-based research for intraperitoneal chemotherapy in epithelial ovarian cancer
    Lois Almadrones
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin J Oncol Nurs 11:211-6. 2007
    ....
  3. ncbi request reprint Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group
    David H Moore
    Department of Obstetrics Gynecology, Indiana University School of Medicine, Indianapolis, IN, USA
    J Clin Oncol 21:4207-13. 2003
    ..The purpose of this study was to determine whether amifostine (WR-2721) prevents or ameliorates clinically significant (grade 2 to 4) neurotoxicity associated with cisplatin and 3-hour paclitaxel chemotherapy. Materials and..
  4. ncbi request reprint Chemotherapy-induced peripheral neuropathy
    Terri Armstrong
    Department of Neuro Oncology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Oncol Nurs Forum 32:305-11. 2005
    ..To review the literature documenting the scope, treatment, and prevention of chemotherapy-induced neuropathy...